Perioperative Management of Pradaxa for Hip Surgery
Introduction to Perioperative Anticoagulation Management
- The American Society of Anesthesiologists recommends discontinuing Pradaxa 4 days (96 hours) before hip surgery if creatinine clearance is ≥50 mL/min, or 5 days (120 hours) if CrCl is 30-50 mL/min, to minimize the risk of bleeding @1, 2
Risk Classification and Stratification
- Hip replacement is classified as a high hemorrhagic risk procedure requiring minimal to no residual anticoagulant effect at the time of surgery, as surgical hemostasis cannot be performed safely with residual anticoagulation @1, 2
Specific Hold Duration Based on Renal Function
- For patients with creatinine clearance ≥50 mL/min, stop Pradaxa 4 days (96 hours) before surgery @1, 2
- For patients with creatinine clearance 30-50 mL/min, stop Pradaxa 5 days (120 hours) before surgery @1, 2
Additional Risk Factors Requiring Extended Hold
- Consider extending the discontinuation period up to 5 days in patients with age >80 years @1, 2, 3
- Consider extending the discontinuation period up to 5 days in patients with concomitant P-glycoprotein inhibitors @1, 2, 3
Critical Timing Considerations
- Obtain a recent creatinine clearance measurement before determining the hold duration to ensure adequate drug clearance @1, 2, 3
- The goal is to achieve 4-5 drug half-lives of interruption for high-bleed-risk procedures @3
Bridging Anticoagulation
- Do not use preoperative heparin bridging when discontinuing Pradaxa for hip surgery, as it increases bleeding risk without clear benefit @1, 2, 3
Resumption After Surgery
- Resume Pradaxa 48-72 hours after hip surgery, provided adequate hemostasis has been established and there is no ongoing bleeding @1, 2, 3
Biological Monitoring
- Routine biological monitoring of dabigatran levels is not needed when recommended interruption periods are followed @1, 2